Klow
GHK-Cu 55mg + BPC-157 12mg + TB-500 12mg + KPV 12mg
The full picture
What Klow is — in plain English.
An educational overview: what it is, what people use it for, how it works, and who it is not for. This is not a grade or a claim of effectiveness.
What's in it
| PEPTIDE | DOSE | ROLE IN THIS BLEND |
|---|---|---|
| GHK-Cu | 55mg | The renewal signal. A copper-binding peptide that supports collagen and elastin production, skin remodeling, and connective-tissue repair. |
| BPC-157 | 12mg | The protector. Contributes general tissue repair and anti-inflammatory support underneath the skin-focused effect. |
| TB-500 | 12mg | The circulation piece. Promotes cell migration and new blood vessel formation, supporting circulation to the skin and connective tissue. |
| KPV | 12mg | The inflammation control. Calms excess inflammatory signaling without suppressing normal immune function, rounding out the repair-and-renewal focus. |
The combination logic
This is the same idea as Glow, with one addition: KPV, which calms excess inflammation without shutting down the immune system’s normal work. The thinking is that inflammation can slow skin and tissue renewal, so controlling it alongside the repair process may support better results than repair alone. Doses here run modestly above the market-standard ratio for this combination — same proportions, scaled up. Clinical detail: GHK-Cu, BPC-157, and TB-500 act as described for Glow. KPV, the C-terminal tripeptide of alpha-MSH, inhibits NF-κB activation — the transcription factor driving inflammatory cytokine production — without broadly suppressing immune competence. Its addition is proposed to reduce inflammatory interference with the collagen-synthesis and angiogenic processes the other three peptides support. The 55/12/12/12mg dosing here is a proportional increase (roughly 10–20%) over the market-standard 50/10/10/10mg ratio, preserving the same relative balance between components.
Is there evidence for the combination, or only for the parts? The evidence picture for GHK-Cu, BPC-157, and TB-500 is the same as described for Glow. KPV has supportive laboratory and mechanistic data for its anti-inflammatory action but limited human trial evidence for the skin-specific use implied here. No study has tested this four-peptide combination at any dose, and no study has specifically tested this scaled-up ratio against the more common 50/10/10/10mg version.
What it's used for
| USED FOR | IN SHORT |
|---|---|
| Skin firmness, collagen support | Same GHK-Cu-driven rationale as Glow, with an added anti-inflammatory component. |
| Comprehensive tissue repair with inflammation control Post-procedural or post-injury skin recovery | The addition of KPV is intended to address inflammation alongside the structural repair the other three peptides support. A commonly cited use for this four-peptide combination, extending Glow’s rationale. |
Overlaps & stacked risks
- All risks described for Glow apply here as well.
- KPV can cause transient headache, fatigue, or injection-site irritation in sensitive patients.
- Combining four active peptides carries the summed risk profile of all four.
- Patients with a highly reactive immune profile should be monitored for unexpected sensitivity.
Who it is not for
- Pregnant or breastfeeding patients
- Patients with copper-metabolism disorders — GHK-Cu delivers bioavailable copper and should be monitored in extended use
- Anyone with a personal or family history of cancer, without physician clearance, given TB-500’s angiogenic mechanism
- Anyone with a highly reactive immune profile — monitor for unexpected sensitivity to the added KPV component
Who it suits
Patients seeking the same skin and tissue-repair support as Glow, who also want inflammation control included, and who have no copper-metabolism disorder, active malignancy concern, or highly reactive immune history.
Who makes this, and under what rules
Everything dispensed here is prepared by a licensed 503A compounding pharmacy — not bought from a supplier and repackaged, and not sourced from an online seller. That designation carries specific, enforceable obligations:
- A prescription in your name. Compounded from a prescription for one identified patient, after an evaluation.
- Licensed and inspected. A state license, subject to inspection by the state board of pharmacy.
- Sterile preparation to a published standard. USP standards.
- A paper trail. A lot number and beyond-use date on every preparation.
A compounded preparation is not an FDA-approved medicine — but it is the difference between a licensed pharmacy working to a standard and an unregulated website. This page describes Klow for general educational purposes. It is not medical advice and does not replace a consultation with a licensed provider. Individual results vary, and combination products carry the risks of each included peptide.
Products are available only by prescription after a consultation with a licensed provider, who decides whether treatment is appropriate. Many compounds described here are not FDA-approved medicines and have not been tested in people for the uses described; information on this site is educational and is not medical advice.